Nektar Therapeutics (NASDAQ:NKTR)
| 0.7333 Delayed Data As of Mar 29 |  +0.0158 / +2.22%Today’s Change | 0.71 Today|||52-Week Range 6.26 | -67.55% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $138.4M |
Company Description
Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes therapies for oncology, immunology and virology. The firm focuses on using new chemistry approaches to make medicines to treat cancer and autoimmune diseases. The company was founded in 1990 and is headquartered in San Francisco, CA.
Contact Information
Nektar Therapeutics 455 Mission Bay Boulevard South San Francisco California 94158 |
Employees
Shareholders
| Mutual fund holders | 73.85% |
| Individual stakeholders | 3.19% |
| Other institutional | 15.87% |
Top Executives
| Howard W. Robin | President, Chief Executive Officer & Director |
| Jillian B. Thomsen | Senior VP, Chief Financial & Accounting Officer |
| Kevin Brodbeck | Senior Vice President-Technical Operations |
| Jonathan Zalevsky | Chief Research & Development Officer |
| Brian L. Kotzin | Chief Medical Officer & Senior Vice President |
